Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases

Citations Over TimeTop 17% of 2011 papers

Abstract

New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with K(i) < 10 nM) but also excellent potencies in a human whole blood assay (IC(50) < 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).

Related Papers

• → Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel(2005)39 cited
• → Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death(2013)10 cited
• → Pharmacological rescue of hERG currents carried out by G604S and wide type hERG co‐expression(2016)2 cited
• → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)